Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Revance Therapeutics, Inc. (RVNC)
|
Add to portfolio |
|
|
|
| Price: |
$17.07
| | Metrics |
| OS: |
88.0
|
M
| |
|
|
| Market cap: |
$1.5
|
B
| |
|
|
|
Net debt:
|
$60.6
|
M
| |
|
|
|
EV:
|
$1.56
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 77.8 | 15.3 | 0.4 | 3.7 | 0.3 | 0.3 | 0.3 | 0.4 |
| Revenue growth | 407.7% | 3610.7% | -88.9% | 1323.3% | -12.7% | 0.0% | -21.7% | -37.9% |
| Cost of goods sold | 366.5 | 294.6 | 164.9 | 146.4 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | -288.7 | -279.2 | -164.5 | -142.6 | 0.3 | 0.3 | 0.3 | 0.4 |
| Gross margin | -371.0% | -1822.1% | -39820.6% | -3825.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 198.8 | 151.8 | 62.0 | 53.9 | 37.4 | 29.1 | 25.1 | 19.0 |
| Research and development | 116.3 | 125.8 | 102.9 | 92.5 | 80.4 | 50.4 | 47.5 | 33.4 |
| EBITA | -258.7 | -266.0 | -164.5 | -142.6 | -117.5 | -79.2 | -72.3 | -52.1 |
| EBITA margin | -332.5% | -1735.5% | -39820.6% | -3825.0% | -44846.2% | -26385.3% | -24105.7% | -13590.1% |
| Amortization of intangibles | 16.0 | 7.2 | | | | | | |
| EBIT | -274.7 | -273.2 | -164.5 | -142.6 | -117.5 | -79.2 | -72.3 | -52.1 |
| EBIT margin | -353.1% | -1782.5% | -39820.6% | -3825.0% | -44846.2% | -26385.3% | -24105.7% | -13590.1% |
| Pre-tax income | -281.3 | -284.8 | -159.4 | -142.6 | -120.6 | -89.3 | -73.5 | -62.9 |
| Income taxes | 0.0 | -0.1 | 0.0 | -3.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 2.1% | 0.0% | 0.0% | 0.0% | |
| Net income | -281.3 | -282.1 | -159.4 | -139.6 | -120.6 | -89.3 | -73.5 | -62.9 |
| Net margin | -361.6% | -1840.7% | -38602.7% | -3742.8% | -46025.6% | -29756.7% | -24500.0% | -16423.0% |
| |
| Diluted EPS | ($4.17) | ($4.86) | ($3.67) | ($3.86) | ($4.01) | ($3.18) | ($3.02) | ($3.24) |
| Shares outstanding (diluted) | 67.5 | 58.0 | 43.5 | 36.2 | 30.1 | 28.1 | 24.3 | 19.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|